Inderal Xl (propranolol HCl)

Since there is no consistent interpatient correlation between the dosage of propranolol hydrochloride and therapeutic response, especially after oral administration, dosage must be carefully individualized according to the response of the patient. If patients are switched from the conventional tablets to the extended-release capsules, care should be taken to ensure that the desired therapeutic effect is maintained. The extended-release capsules should not be considered a simple substitute for the conventional tablets on a mg-for-mg basis, since the capsules produce lower blood concentrations. If patients are switched to the extended-release capsules, the need for dosage retitration should be considered, especially to maintain effectiveness at the end of the dosing interval.

The manufacturers of propranolol hydrochloride injection state that a reduction in the dosage of propranolol hydrochloride may be necessary in geriatric patients.

The manufacturers of propranolol hydrochloride injection state that a reduction in the dosage of propranolol hydrochloride may be necessary in patients with hepatic impairment.

Propranolol hydrochloride is usually administered orally. When administered orally in divided doses, the drug should be given before meals and at bedtime. When propranolol hydrochloride extended-release capsules are administered, the entire daily dose is given once daily. When propranolol hydrochloride oral concentrate solution is used, the dose should be diluted (e.g., with water, juice, carbonated beverages) or mixed with semisolid foods (e.g., applesauce, puddings) just prior to administration.

For the treatment of cardiac arrhythmias, propranolol has been given IV. Oral therapy should replace IV therapy as soon as possible.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

There are no adequate and well-controlled studies to date using propranolol in pregnant women. Safe use of propranolol during pregnancy has not been established. Low birthweight infants with respiratory distress and hypoglycemia have been born to women who received propranolol throughout pregnancy. Bradycardia, hypoglycemia, and respiratory depression also have been reported in neonates whose mothers received propranolol at parturition; adequate facilities for monitoring such infants at birth should be available. The manufacturers state that the drug should be used during pregnancy only when the possible benefits outweigh the potential risks to the fetus.

Embryotoxicity (reduced litter size, increased resorption rates) and neonatal toxicity (deaths) have been reported in reproductive studies in rats receiving propranolol hydrochloride 150 mg/kg daily by gavage or in the diet throughout pregnancy and lactation; however, such effects were not observed in rats receiving 80 mg/kg daily (equivalent to the maximum recommended human dosage on a mg/m2 basis). No evidence of embryotoxicity or neonatal toxicity was observed in rabbits receiving oral doses of propranolol hydrochloride of up to 150 mg/kg daily (about 5 times the maximum recommended oral human daily dose) throughout pregnancy and lactation.

Since propranolol is distributed into milk, the drug should be used with caution in nursing women.

No enhanced messaging available.